Shaji Kumar
Mayo Clinic · Mayo · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shaji Kumar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:48 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07285239 · Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaPrECOG, LLC. · recruiting · Multiple Myeloma · study chair
- Ph1/Ph2NCT03915184 · Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)CARsgen Therapeutics Co., Ltd. · active not recruiting · Multiple Myeloma · principal investigator
- Ph1NCT03399539 · Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple MyelomaMayo Clinic · completed · Recurrent Plasma Cell Myeloma, T(11;14) · principal investigator
- Ph2NCT03289299 · Aggressive Smoldering Curative Approach Evaluating Novel Therapies and TransplantInternational Myeloma Foundation · active not recruiting · Smoldering Multiple Myeloma · principal investigator
- Ph2NCT03012880 · Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaMayo Clinic · completed · Plasma Cell Myeloma · principal investigator
- Ph2NCT02880228 · Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell TransplantMayo Clinic · completed · Plasma Cell Myeloma · principal investigator
- Ph1/Ph2NCT02633059 · Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaMayo Clinic · completed · Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma · principal investigator
- Ph2NCT02547662 · Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaMayo Clinic · completed · Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma · principal investigator
- Ph1NCT01936090 · Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple MyelomaMayo Clinic · completed · DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma · principal investigator
- Ph1/Ph2NCT01864018 · Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain AmyloidosisMayo Clinic · completed · Amyloidosis, Plasma Cell Myeloma · principal investigator
- Ph3NCT01863550 · Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaECOG-ACRIN Cancer Research Group · active not recruiting · Plasma Cell Myeloma · principal investigator
- Ph2NCT01812720 · Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell TransplantMayo Clinic · withdrawn · Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma · principal investigator
- Ph2NCT01794039 · Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With LenalidomideMayo Clinic · completed · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph1NCT01711528 · Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNational Cancer Institute (NCI) · completed · Recurrent Plasma Cell Myeloma · principal investigator
- Ph2NCT01096342 · Dinaciclib in Treating Patients With Relapsed or Refractory Multiple MyelomaNational Cancer Institute (NCI) · completed · Refractory Multiple Myeloma · principal investigator
- Ph2NCT01078441 · Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell TransplantNational Cancer Institute (NCI) · terminated · Refractory Multiple Myeloma · study chair
- Ph2NCT01072773 · Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain AmyloidosisMayo Clinic · completed · Primary Systemic Amyloidosis · study chair
- Ph2NCT00998049 · Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell TransplantMayo Clinic · completed · Multiple Myeloma, Refractory Multiple Myeloma, Stage I Multiple Myeloma · study chair
- Ph1/Ph2NCT00918333 · Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaMayo Clinic · completed · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma · principal investigator
- Ph2NCT00514137 · Sunitinib in Treating Patients With Relapsed Multiple MyelomaNational Cancer Institute (NCI) · completed · Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma · principal investigator
- Ph1NCT00303797 · Sorafenib and Bortezomib in Treating Patients With Advanced CancerNational Cancer Institute (NCI) · completed · Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Impact of Genetic susceptibility along the continuum from MGUS to MMU01CA271014 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2022 to 2026 · $617,059 awarded in 2026Same name and institution; not confirmed by an ID
- Onset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2012 to 2024 · $78,948 awarded in 2024Same name and institution; not confirmed by an ID
- Clinical Protocol and Data ManagementP30CA015083 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2019 to 2022 · $558,028 awarded in 2022Grant number is on one of their registry trials
- Project 2 - IMiD Resistance in Patients and Humanized Mice with Multiple MyelomaU54CA224018 · NCI · MAYO CLINIC ARIZONA · fiscal years 2019 to 2021 · $314,462 awarded in 2021Same name and institution; not confirmed by an ID
- Prevalence and Progression of Monoclonal GammopathiesR01CA107476 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2014 to 2018 · $321,975 awarded in 2018Same name and institution; not confirmed by an ID
- The Role of Cereblon Pathways in MyelomaR01CA183968 · NCI · MAYO CLINIC ARIZONA · fiscal years 2014 to 2018 · $446,267 awarded in 2018Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT01863550
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT01863550, NCT01078441
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT01863550
- Translation of Novel Therapeutic Targets in Multiple MyelomaR01CA167511 · NCI · MAYO CLINIC ARIZONA · PI ALEXANDER KEITH STEWART · fiscal years 2013 to 2017Named on NCT01711528
- Phase I Clinical Trials of Anticancer AgentsU01CA069912 · NCI · MAYO CLINIC ROCHESTER · PI CHARLES ERLICHMAN · fiscal years 1995 to 2013Named on NCT01711528, NCT00303797
- NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 EmphasisUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ALEX A. ADJEI · fiscal years 2014 to 2019Named on NCT01711528
- Wisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI Salma Jabbour, GLENN LIU · fiscal years 2014 to 2019Named on NCT01711528
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:48 UTC. The ranking covers the 200 most relevant of 879 PubMed records, and a shared surname and initials can bring in a namesake. All 879 on PubMed
- 1,945 citationsRCR 122.3
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med · 2016873 citationsRCR 28.4
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.N Engl J Med · 2019853 citationsRCR 33.9
- 348 citationsRCR 14.4
- 337 citationsRCR 19.3
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.J Clin Oncol · 2020251 citationsRCR 9.8
- A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study.J Am Coll Cardiol · 2003247 citationsRCR 7.6
- Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.J Clin Oncol · 2020242 citationsRCR 11.2
- 232 citationsRCR 10.3
- Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.N Engl J Med · 2019181 citationsRCR 8.5